BFRI
Biofrontera, Inc.
BFRI
Key terms
About BFRI
Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. It specializes in the treatment of dermatological conditions, caused primarily by exposure to sunlight that results in sun damage to the skin. The company is focused on the treatment of actinic keratosis and markets a topical antibiotic for treatment of impetigo. Its products include Ameluz and Xepi, its two prescription drugs, and BF-RhodoLED, a lamp used with Ameluz, for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company was founded on March 3, 2015 and is headquartered in Woburn, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BFRI news
Aug 16 7:35am ET Benchmark Co. Reaffirms Their Buy Rating on Biofrontera (BFRI) by TipRanks Aug 14 4:37pm ET Biofrontera Inc. reports Q2 EPS (5c), consensus (77c) by TipRanks Jun 24 8:53am ET Biofrontera Inc. announces launch of RhodoLED XL lamp by TipRanks Jun 14 5:19pm ET Biofrontera Stockholders Approve Key Governance Decisions by TipRanks Jun 06 8:03am ET Analysts Offer Insights on Healthcare Companies: Biofrontera (BFRI), Gilead Sciences (GILD) and Ventyx Biosciences (VTYX) by TipRanks
No recent press releases are available for BFRI
BFRI Financials
1-year income & revenue
Key terms
Ad Feedback
BFRI Forecasts
analyst rating
- buy
- hold
- sell
We're sorry, but this
information is
temporarily unavailable.
1-year stock price forecast
BFRI Competitors
$ Market cap P/E ratio $ Price 1d change 52-week range
